Declaration of Conformity

as per Annex IV of the Directive 98/79/EC of the European Parliament and the Council of 27 October 1998 via BSI as the Notified Body (registration no. BSI-NL 2797)

Document No.:	**DOC-2022-10**
Manufacturer:	**Roche Molecular Systems, Inc.** **1080 US Highway 202 South** **Branchburg, NJ 08876** **USA**
Authorized Representative:	**Roche Diagnostics GmbH** **Sandhofer Strasse 116** **68305 Mannheim** **Germany**
Name, Address and Identification number of the Notified Body:	**BSI Group The Netherlands B.V.** **Notified Body Number: 2797** **Say Building, John M. Keynesplein 9, 1066 EP** **Amsterdam, Netherlands**

Roche Molecular Systems, Inc. declares that the *in vitro* diagnostic medical device:

Product Name:	**cobas**® HCV *Quantitative nucleic acid test for use on the* ***cobas***® *5800/6800/8800 Systems*
P/N:	09040765190
	Description: **cobas**® HCV is an *in vitro* nucleic acid amplification test for both the detection and quantitation of hepatitis C (HCV) RNA, genotypes 1 to 6, in human EDTA plasma or serum of HCV-infected individuals. The complete Intended Use is contained in the **cobas**® HCV Package Insert.

Complies with the requirements of the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices.

This declaration is supported by the following certificates:
EC Certificate – Full Quality Assurance: CE 707974, first issued 2019-03-26, valid until 2025-05-26
EC Design-Examination Certificate: CE 708020, first issued 2019-03-26, valid until 2025-05-26

The Manufacturer agrees to develop, implement, and maintain a documented post-production monitoring process, including the notification of reportable events, under the European Medical Device Vigilance System Guidelines. As a legal manufacturer, Roche Molecular Systems, Inc., is solely responsible for the product. This declaration is issued under the sole responsibility of Roche Molecular Systems, Inc.

Declaration of Conformity

as per Annex IV of the Directive 98/79/EC of the European Parliament and the Council of 27 October 1998 via BSI as the Notified Body (registration no. BSI-NL 2797)

Document No.: **DOC-2022-10**

Place: Tucson, AZ

Date: 19-May-2022

Jeff Boone

Jeff Boone
Vice President, Quality Management

Place: Pleasanton, CA

Date: 17-May-2022

Rita Hoady

Rita Hoady
Network Lead Molecular Lab
Director, Global Regulatory Affairs